Description

The global companion diagnostics market is set to grow by US$ 6.44 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.7% during the forecast period, according to data and analytics company StrategyHelix. Rising geriatric population, rising prevalence of cancer, companies promoting personalized medicine and targeted therapy as new treatment options, co-development of drugs and diagnostics are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for companion diagnostics. The global companion diagnostics market is segmented on the basis of product, technology, indication, and region. By product, it is categorized into consumables, instruments, and services. The consumables segment held the largest market share in 2020. By technology, the companion diagnostics market is divided into immunohistochemistry (IHC), polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), and others. The polymerase chain reaction (PCR) segment accounted for the largest market share in 2020. Based on indication, the companion diagnostics market is divided into lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, and others.

The report has profiled some of the key players of the market such as Abbott Laboratories, Agilent Technologies Inc. (Dako A/S), ARUP Laboratories Inc., bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., MolecularMD Corp. (ICON plc), Myriad Genetic Laboratories Inc., QIAGEN N.V., Thermo Fisher Scientific Inc..

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the companion diagnostics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: consumables, instruments, and services
Technology: immunohistochemistry (IHC), polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), and others
Indication: lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the global companion diagnostics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global companion diagnostics market looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Companion Diagnostics Market by Product
4.1 Consumables
4.2 Instruments
4.3 Services
5. Companion Diagnostics Market by Technology
5.1 Immunohistochemistry (Ihc)
5.2 Polymerase Chain Reaction (Pcr)
5.3 In Situ Hybridization (Ish)
5.4 Next-Generation Sequencing (Ngs)
5.5 Others
6. Companion Diagnostics Market by Indication
6.1 Lung Cancer
6.2 Breast Cancer
6.3 Colorectal Cancer
6.4 Leukemia
6.5 Melanoma
6.6 Others
7. Companion Diagnostics Market by Region
7.1 North America
7.2 Asia Pacific
7.3 Europe
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 Abbott Laboratories
8.2 Agilent Technologies Inc. (Dako A/S)
8.3 ARUP Laboratories Inc.
8.4 bioMerieux SA
8.5 Danaher Corporation
8.6 F. Hoffmann-La Roche Ltd.
8.7 Illumina Inc.
8.8 MolecularMD Corp. (ICON plc)
8.9 Myriad Genetic Laboratories Inc.
8.10 QIAGEN N.V.
8.11 Thermo Fisher Scientific Inc.
9. Appendix
9.1 About StrategyHelix
9.2 Disclaimer